FY2025 EPS Estimates for Certara Lowered by Leerink Partnrs

Certara, Inc. (NASDAQ:CERT) – Analysts at Leerink Partnrs reduced their FY2025 EPS estimates for Certara in a note issued to investors on Sunday, November 17th. Leerink Partnrs analyst M. Cherny now anticipates that the company will post earnings of $0.32 per share for the year, down from their previous estimate of $0.33. The consensus estimate for Certara’s current full-year earnings is $0.28 per share. Leerink Partnrs also issued estimates for Certara’s FY2027 earnings at $0.40 EPS.

Certara (NASDAQ:CERT) last issued its quarterly earnings results on Wednesday, November 6th. The company reported $0.13 EPS for the quarter, topping analysts’ consensus estimates of $0.11 by $0.02. The company had revenue of $94.80 million during the quarter, compared to analysts’ expectations of $95.51 million. Certara had a positive return on equity of 3.43% and a negative net margin of 8.34%. The firm’s revenue was up 10.7% compared to the same quarter last year. During the same quarter in the previous year, the firm posted $0.06 EPS.

CERT has been the topic of several other reports. Barclays dropped their price objective on shares of Certara from $14.00 to $12.00 and set an “equal weight” rating on the stock in a report on Thursday, November 7th. UBS Group raised Certara from a “neutral” rating to a “buy” rating and set a $16.00 price target on the stock in a research report on Friday, September 27th. Finally, Robert W. Baird reduced their price objective on Certara from $18.00 to $13.00 and set a “neutral” rating for the company in a research note on Tuesday, November 5th. Six investment analysts have rated the stock with a hold rating and two have given a buy rating to the company. According to MarketBeat, Certara currently has an average rating of “Hold” and a consensus price target of $15.92.

Certara Price Performance

Shares of NASDAQ:CERT opened at $9.88 on Tuesday. Certara has a twelve month low of $9.72 and a twelve month high of $19.87. The company has a current ratio of 2.86, a quick ratio of 2.86 and a debt-to-equity ratio of 0.28. The company has a market cap of $1.59 billion, a PE ratio of -49.40, a price-to-earnings-growth ratio of 5.04 and a beta of 1.51. The company’s 50 day moving average is $10.85 and its 200 day moving average is $13.33.

Insiders Place Their Bets

In other Certara news, insider Leif E. Pedersen sold 51,224 shares of the firm’s stock in a transaction that occurred on Monday, September 9th. The stock was sold at an average price of $11.29, for a total value of $578,318.96. Following the sale, the insider now directly owns 99,704 shares of the company’s stock, valued at approximately $1,125,658.16. This trade represents a 33.94 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, insider Patrick F. Smith sold 5,409 shares of the company’s stock in a transaction that occurred on Monday, October 7th. The stock was sold at an average price of $11.03, for a total value of $59,661.27. Following the transaction, the insider now directly owns 50,091 shares of the company’s stock, valued at approximately $552,503.73. The trade was a 9.75 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders own 2.39% of the company’s stock.

Institutional Investors Weigh In On Certara

Several institutional investors and hedge funds have recently added to or reduced their stakes in the stock. Sei Investments Co. grew its position in shares of Certara by 39.5% in the second quarter. Sei Investments Co. now owns 997,871 shares of the company’s stock valued at $13,821,000 after purchasing an additional 282,357 shares during the period. Silvercrest Asset Management Group LLC boosted its holdings in Certara by 27.3% in the 1st quarter. Silvercrest Asset Management Group LLC now owns 516,300 shares of the company’s stock worth $9,231,000 after buying an additional 110,636 shares during the last quarter. Daventry Group LP increased its stake in Certara by 153.0% during the 2nd quarter. Daventry Group LP now owns 1,308,572 shares of the company’s stock worth $18,124,000 after buying an additional 791,405 shares in the last quarter. Kayne Anderson Rudnick Investment Management LLC raised its holdings in shares of Certara by 8.4% during the second quarter. Kayne Anderson Rudnick Investment Management LLC now owns 810,206 shares of the company’s stock valued at $11,221,000 after acquiring an additional 62,912 shares during the last quarter. Finally, Clearbridge Investments LLC lifted its position in shares of Certara by 0.8% in the first quarter. Clearbridge Investments LLC now owns 4,173,195 shares of the company’s stock valued at $74,617,000 after acquiring an additional 32,846 shares in the last quarter. Hedge funds and other institutional investors own 73.96% of the company’s stock.

About Certara

Certara, Inc, together with its subsidiaries, provides software products and technology-enabled services to customers for biosimulation in drug discovery, preclinical and clinical research, regulatory submissions, and market access in the United States and internationally. It offers solutions for model-informed drug development, as well as biosimulation solution used to predict both pharmacokinetics and pharmacodynamics.